GlobeNewsWire
16 Nov 2026, 08:30 UTC · 16h ago
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
Impact · against what's priced in
Aclaris creates a potential valuation catalyst by initiating a Phase 2b trial for modzatinib in lichen planus, a market currently devoid of approved therapies. The ability to target both T-cell receptor signaling and effector cytokine signaling provides a unique mechanism for a first-of-its-kind oral therapy.
- ACRS+0.60
No priced-in read yet





